Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Literature DB >> 10665477

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Abstract

The year 2000 will be a significant date for the field of Ras-related therapies since numerous agents will have Phase II clinical efficacy data maturing to provide proof of principle for this cancer treatment strategy. These data will also provide an important milestone for the cancer research community since these molecules represent a small vanguard of oncology drug discovery projects predicated on molecular targets. We can only hope that these agents are a successful harbinger for the formidable number of targeted therapies that will be entering development pipelines in the coming years.

Entities: Disease

Mesh：

Substances：

Year: 1999 PMID： 10665477 DOI： 10.1023/a:1006380320290

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

105 in total

1. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.

Authors: C L Strickland; P C Weber; W T Windsor; Z Wu; H V Le; M M Albanese; C S Alvarez; D Cesarz; J del Rosario; J Deskus; A K Mallams; F G Njoroge; J J Piwinski; S Remiszewski; R R Rossman; A G Taveras; B Vibulbhan; R J Doll; V M Girijavallabhan; A K Ganguly
Journal: J Med Chem Date: 1999-06-17 Impact factor: 7.446

2. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors: K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal: Nature Date: 1987 May 28-Jun 3 Impact factor: 49.962

3. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors: T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal: Nature Date: 1992-04-23 Impact factor: 49.962

4. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

Authors: T Mukhopadhyay; M Tainsky; A C Cavender; J A Roth
Journal: Cancer Res Date: 1991-03-15 Impact factor: 12.701

5. Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors: S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal: Science Date: 1994-08-12 Impact factor: 47.728

6. H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate.

Authors: K E Hightower; C C Huang; P J Casey; C A Fierke
Journal: Biochemistry Date: 1998-11-03 Impact factor: 3.162

7. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

Authors: S Shirasawa; M Furuse; N Yokoyama; T Sasazuki
Journal: Science Date: 1993-04-02 Impact factor: 47.728

8. Differential effects of monoterpenes and lovastatin on RAS processing.

Authors: R J Hohl; K Lewis
Journal: J Biol Chem Date: 1995-07-21 Impact factor: 5.157

9. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.

Authors: M Yonemoto; T Satoh; H Arakawa; I Suzuki-Takahashi; Y Monden; T Kodera; K Tanaka; T Aoyama; Y Iwasawa; T Kamei; S Nishimura; K Tomimoto
Journal: Mol Pharmacol Date: 1998-07 Impact factor: 4.436

10. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

Authors: T Nagasu; K Yoshimatsu; C Rowell; M D Lewis; A M Garcia
Journal: Cancer Res Date: 1995-11-15 Impact factor: 12.701

10 in total

1. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.

Authors: Sarah J O'Meara; B Therese Kinsella
Journal: Br J Pharmacol Date: 2004-08-31 Impact factor: 8.739

2. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors: Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal: Neuro Oncol Date: 2014-02-04 Impact factor: 12.300

3. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.

Authors: Brigitte C Widemann; Robert J Arceci; Nalini Jayaprakash; Elizabeth Fox; Peter Zannikos; Wendy Goodspeed; Anne Goodwin; John J Wright; Susan M Blaney; Peter C Adamson; Frank M Balis
Journal: Pediatr Blood Cancer Date: 2010-09-21 Impact factor: 3.167

4. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors: Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev Estrov; Srdan Verstovsek; Susan O'Brien; Stefan Faderl; Deborah A Thomas; John J Wright; Jorge Cortes
Journal: Cancer Date: 2010-10-19 Impact factor: 6.860

5. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Authors: Jeffrey E Lancet; Ivana Gojo; Jason Gotlib; Eric J Feldman; Jacqueline Greer; Jane L Liesveld; Laura M Bruzek; Lawrence Morris; Youn Park; Alex A Adjei; Scott H Kaufmann; Elizabeth Garrett-Mayer; Peter L Greenberg; John J Wright; Judith E Karp
Journal: Blood Date: 2006-11-02 Impact factor: 22.113

Review 6. Drug development in pancreatic cancer: finally, biology begets therapy.

Authors: Steven J Cohen; Neal J Meropol
Journal: Int J Gastrointest Cancer Date: 2002

7. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.

Authors: Fredrik Wärnberg; Daniel White; Elizabeth Anderson; Fiona Knox; Robert B Clarke; Julie Morris; Nigel J Bundred
Journal: Breast Cancer Res Date: 2006-04-12 Impact factor: 6.466